IQV earnings

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http://ir.iqvia.com. To par

Revenue of $4,364 million for the fourth quarter, $16,310 million for the full year GAAP Net Income of $514 million for the fourth quarter, $1,360 million for the full year Adjusted EBITDA of $1,046 million for the fourth quarter, $3,788 million for the full year GAAP Diluted Earnings per Share of $2.99 for the fourth quarter, $7.84 for the full year Adjusted Diluted Earnings per Share of $3.42 for the fourth quarter, $11.92 for the full year R&D Solutions quarterly bookings of over $2.7 billion, representing a book-to-bill ratio of 1.18x R&D Solutions contracted backlog of $32.7 billion, up 5.3% year-over-year R&D Solutions Revenue of $2,333 million for the fourth qua

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http:/

Revenue of $4,100 million, up 5.2 percent year-over-year GAAP Net Income of $331 million, Adjusted EBITDA of $949 million GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year Operating Cash Flow of $908 million; Free Cash Flow of $772 million, up 35 percent year-over-year, representing 150 percent of Adjusted Net Income IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com.

Revenue of $4,017 million, up 5.3 percent year-over-year GAAP Net Income of $266 million, Adjusted EBITDA of $910 million GAAP Diluted Earnings per Share of $1.54, Adjusted Diluted Earnings per Share of $2.81 R&D Solutions quarterly bookings of $2.5 billion, representing a book-to-bill ratio of 1.12x R&D Solutions contracted backlog of $32.1 billion, up 5.1 percent year-over-year TAS Revenue of $1,628 million, up 8.9 percent year-over-year Repurchased $607 million of common stock in the quarter, over $1 billion year-to-date IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. T

Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, part

Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported year-over-year TAS Revenue of $1,554 million, up 8.6 percent year-over-year Operating Cash Flow of $721 million, bringing year-to-date Operating Cash Flow to $1,831 million, up 31 percent year-over-year Free Cash Flow of $571 million, bringing year-to-date Free Ca

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will re

Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year Full-year 2024 guidance updated for revenue to be between $15,425 million and $15,525 million, Adjusted EBITDA between $3,705 million and $3,765 million, and Adjusted Diluted Earnings per Share between $11.10 and $11.30 IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global pro

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will recei

Revenue of $3,737 million GAAP Net Income of $288 million, Adjusted EBITDA of $862 million GAAP Diluted Earnings per Share of $1.56, Adjusted Diluted Earnings per Share of $2.54 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.23x R&D Solutions contracted backlog of $30.1 billion, up 7.9 percent year-over-year IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024. First-Quarter 2024 Operating Results Revenue for the first quarter of $3,737 millio

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2024 financial results before the market opens on Thursday, May 2, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receiv

Revenue of $3,868 million for the fourth quarter, $14,984 million for the full year GAAP Net Income of $469 million for the fourth quarter, $1,358 million for the full year Adjusted EBITDA of $966 million for the fourth quarter, $3,569 million for the full year GAAP Diluted Earnings per Share of $2.54 for the fourth quarter, $7.29 for the full year Adjusted Diluted Earnings per Share of $2.84 for the fourth quarter, $10.20 for the full year R&D Solutions quarterly bookings of over $2.8 billion, representing book-to-bill ratio of 1.31x R&D Solutions contracted backlog of $29.7 billion grew 9.2 percent year-over-year Full-year 2024 revenue guidance of $15,400 million to

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, pa

Revenue of $3,736 million grew 4.9 percent year-over-year GAAP Net Income of $303 million grew 7.1 percent year-over-year Adjusted EBITDA of $888 million grew 9.1 percent year-over-year GAAP Diluted Earnings per Share of $1.63 grew 9.4 percent year-over-year Adjusted Diluted Earnings per Share of $2.49 grew 0.4 percent year-over-year R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.24x R&D Solutions contracted backlog of $28.8 billion grew 12 percent year-over-year   IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will

Revenue of $3,728 million grew 5.3 percent year-over-year on a reported basis and 5.5 percent at constant currency GAAP Net Income of $297 million grew 16.0 percent year-over-year Adjusted EBITDA of $864 million grew 8.0 percent year-over-year GAAP Diluted Earnings per Share of $1.59 grew 18.7 percent year-over-year Adjusted Diluted Earnings per Share of $2.43 declined 0.4 percent year-over-year R&D Solutions quarterly bookings of $2.7 billion, representing book-to-bill ratio of 1.28x R&D Solutions contracted backlog of $28.4 billion grew 11 percent year-over-year IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solu

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its second-quarter 2023 financial results before the market opens on Tuesday, August 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will rec

Revenue of $3,652 million GAAP Net Income of $289 million, Adjusted EBITDA of $851 million GAAP Diluted Earnings per Share of $1.53, Adjusted Diluted Earnings per Share of $2.45 R&D Solutions quarterly bookings of $2.6 billion, representing book-to-bill ratio of 1.28x R&D Solutions contracted backlog of $27.9 billion grew 10.1 percent year-over-year and 11.3 percent excluding the impact of foreign exchange Reaffirms full-year 2023 guidance IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will rec

Revenue of $3,739 million for the fourth quarter, $14,410 million for the full year GAAP Net Income of $227 million for the fourth quarter, $1,091 million for the full year Adjusted EBITDA of $920 million for the fourth quarter, $3,346 million for the full year GAAP Diluted Earnings per Share of $1.20 for the fourth quarter, $5.72 for the full year Adjusted Diluted Earnings per Share of $2.78 for the fourth quarter, $10.16 for the full year R&D Solutions quarterly bookings of over $3.1 billion, representing book-to-bill ratio of 1.51x R&D Solutions contracted backlog of $27.2 billion grew 9.6 percent year-over-year and 11.6 percent excluding the impact of foreign exchange IQV

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, partic

Revenue of $3,562 million grew 5.0 percent year-over-year on a reported basis and 10.5 percent at constant currency GAAP Net Income of $283 million grew 8.4 percent year-over-year Adjusted EBITDA of $814 million increased 11.8 percent year-over-year GAAP Diluted Earnings per Share of $1.49 grew 11.2 percent year-over-year Adjusted Diluted Earnings per Share of $2.48 increased 14.3 percent year-over-year R&D Solutions quarterly bookings of over $2.5 billion; excluding pass throughs, quarterly bookings at a historic high of over $2.0 billion, representing a services book-to-bill ratio of 1.39x R&D Solutions contracted backlog of $25.8 billion grew 5.4 percent year-over-year and 9

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2022 financial results before the market opens on Wednesday, October 26, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will r

Revenue of $3,541 million grew 3.0 percent year-over-year on a reported basis and 7.1 percent at constant currency GAAP Net Income of $256 million grew 46.3 percent year-over-year Adjusted EBITDA of $800 million grew 10.8 percent year-over-year GAAP Diluted Earnings per Share of $1.34 grew 48.9 percent year-over-year Adjusted Diluted Earnings per Share of $2.44 grew 14.6 percent year-over-year R&D Solutions quarterly bookings continue at historic high of over $2.6 billion R&D Solutions contracted backlog of $25.6 billion grew 7.1 percent year-over-year at actual currency Full-year 2022 revenue guidance updated for foreign exchange IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV),

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its second-quarter 2022 financial results before the market opens on Thursday, July 21, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

Revenue of $3,568 million increased 4.7 percent year-over-year on a reported basis and 6.8 percent at constant currency GAAP Net Income of $325 million grew 53.3 percent year-over-year Adjusted EBITDA of $812 million grew 9.1 percent year-over-year GAAP Diluted Earnings per Share of $1.68 grew 54.1 percent year-over-year Adjusted Diluted Earnings per Share of $2.47 grew 13.3 percent year-over-year Record quarterly R&D Solutions services bookings of over $1.9 billion; record R&D Solutions contracted backlog in excess of $25 billion, up 9.1 percent year-over-year Full-year 2022 revenue guidance range updated for foreign exchange and the Ukraine/Russia crisis Full-year 2022 guid

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2022 financial results before the market opens on Wednesday, April 27, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

Revenue of $3,636 million for the fourth quarter grew 10.2 percent year-over-year on a reported basis and 11.6 percent at constant currency GAAP Net Income of $318 million for the fourth quarter grew 167.2 percent year-over-year Adjusted EBITDA of $828 million for the fourth quarter grew 12.7 percent year-over-year GAAP Diluted Earnings per Share of $1.63 for the fourth quarter grew 167.2 percent year-over-year Adjusted Diluted Earnings per Share of $2.55 for the fourth quarter grew 20.9 percent year-over-year Full-year Operating Cash Flow of $2,942 million grew 50.2 percent year-over-year and record full-year Free Cash Flow of $2,302 million grew 71.4 percent year-over-year Re

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2021 financial results before the market opens on Tuesday, February 15, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participa

RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ:NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial results. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes before the start of the call by dialing (877) 705-6003 (U.S.), (201) 493-6725 (International) Conference ID: 13724953, or through the webcast link NRx Pharmaceuticals Third

Revenue of $3,391 million for the third quarter grew 21.7 percent year-over-year GAAP Net Income of $261 million for the third quarter grew 158.4 percent year-over-year Adjusted EBITDA of $728 million for the third quarter grew 20.5 percent year-over-year GAAP Diluted Earnings per Share of $1.34 for the third quarter grew 157.7 percent year-over-year Adjusted Diluted Earnings per Share of $2.17 for the third quarter grew 33.1 percent year-over-year R&D Solutions contracted backlog of $24.4 billion grew 12.7 percent year-over-year Full-year 2021 guidance raised for revenue, Adjusted EBITDA, and Adjusted Diluted EPS IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global pro

IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2021 financial results before the market opens on Thursday, October 21, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receiv

Revenue of $3,438 million for the second quarter grew 36.4 percent year-over-year GAAP Net Income of $175 million for the second quarter increased from $(23) million in 2020 Adjusted EBITDA of $722 million for the second quarter increased from $483 million in 2020 GAAP Diluted Earnings per Share of $0.90 for the second quarter increased from $(0.12) in 2020 Adjusted Diluted Earnings per Share of $2.13 for the second quarter increased from $1.18 in 2020 R&D Solutions contracted backlog of $23.9 billion grew 16.7 percent year-over-year; next twelve months revenue from backlog increased to $6.6 billion, up 19.6 percent year-over-year Full-year 2021 guidance raised for revenue, Ad